A chart compares 2 popular weight-loss drugs, Ozempic and metformin from cost to risks and benefits Ozempic, or semaglutide, is a new obesity drug, delivered in the form of a hormone injection
doi: 10.1097/MOG.0000000000000423
Amylin replacement with pramlintide in type 1 and type 2 diabetes: a physiological approach to overcome barriers with insulin therapy
Diabetes GLP-1s Show Better Retention but Still Leak Demand GLP-1 therapies prescribed for type 2 diabetes demonstrate stronger patient retention than those indicated for obesity, but the market still faces substantial leakage
Final Takeaway Eating well on GLP-1s doesnt have to feel restrictive -but it does require paying attention to how your body responds to certain foods
Complementary to this, emerging evidence from behavioral science suggests that digital toolssuch as ecological momentary assessment and ecological momentary interventions delivered through apps or wearables, may help sustain behavioral changes and prevent relapse, particularly in the vulnerable post-discontinuation phase [149]